| Literature DB >> 16153259 |
C-C Szeto1, C-B Leung, K-M Chow, B C-H Kwan, M-C Law, A Y-M Wang, S-F Lui, P K-T Li.
Abstract
This study reviewed 1787 episodes of peritoneal dialysis (PD)-related peritonitis in 544 patients between 1994 and 2003. The overall rate of peritonitis was 0.68 episodes/year of PD, but decreased from 1.10 to 0.46 episodes/year between 1994 and 2003. The incidence of peritonitis caused by coagulase-negative staphylococci declined between 1994 and 1998 from 0.21 to 0.06 episodes/year of PD, coinciding with a reduction in the use of spike PD sets. There was a 60.1% response rate to antibiotics throughout the period, but the percentage of cases that required modification of the initial empirical antibiotic regimen rose from 13.6% to 58.7%, indicating that treatment should be individualised.Entities:
Mesh:
Year: 2005 PMID: 16153259 PMCID: PMC7128646 DOI: 10.1111/j.1469-0691.2005.01222.x
Source DB: PubMed Journal: Clin Microbiol Infect ISSN: 1198-743X Impact factor: 8.067
Changes in the peritonitis management protocol in the renal unit during the 10‐year period of the study
| Period | Antibiotic regimen |
|---|---|
| January–December 1994 | Imipenem–cilastatin ± vancomycin |
| January–December 1995 | Ceftazidime + vancomycin |
| January–June 1996 | Cefepime ± vancomycin |
| July 1996 to July 1998 | Cefepime ± vancomycin; or ceftazidime + vancomycin |
| August 1998 to October 1998 | Sulperazone |
| November 1998 to March 1999 | Cefepime ± vancomycin |
| April 1999 to February 2001 | Netilmicin + cefazolin |
| March 2001 to February 2002 | Ceftazidime + cefazolin; or imipenem–cilastatin |
| March 2002 to date | Ceftazidime + cefazolin |
Dosages of all antibiotics generally followed those described by the International Society of Peritoneal Dialysis Ad Hoc Committee [7].
Prospective studies underway [10, 11, 12].
Microbiological causes of peritonitis episodes during a 10‐year period
| Organisms identified | No. of episodes (%) |
|---|---|
| Gram‐positive organisms | 722 (40.4) |
|
| 212 (11.9) |
| MSSA | 174 (9.7) |
| MRSA | 38 (2.1) |
| CNS | 217 (12.1) |
|
| 24 (1.3) |
| Other | 155 (8.7) |
|
| 20 (1.1) |
| Other diphtheroides | 34 (1.9) |
| Others | 60 (3.4) |
| Gram‐negative organisms | 520 (29.1) |
|
| 227 (12.7) |
|
| 13 (0.7) |
|
| 109 (6.1) |
|
| 47 (2.6) |
|
| 45 (2.5) |
| Others | 79 (4.4) |
| Fungi | 45 (2.5) |
|
| 41 (2.3) |
| Filamentous fungi | 4 (0.2) |
| Mycobacteria | 17 (1.0) |
|
| 11 (0.6) |
| Atypical mycobacteria | 6 (0.3) |
| Polymicrobial growth | 192 (10.7) |
| Culture‐negative | 291 (16.3) |
| Total | 1787 |
MSSA, methicillin‐sensitive S. aureus; MRSA, methicillin‐resistant S. aureus; CNS, coagulase‐negative staphylococci.